Compare GSK plc (GSK) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs NetApp Inc. — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while NetApp Inc. trades at $237.15 (market cap $45.38B). The key difference: GSK plc is far larger — about 2× NetApp Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and NetApp Inc. for 56 Days on average.
| GSK | NTAP | |
|---|---|---|
Market Cap | $91.88B | $45.38B |
Volume | 7,730,529 | 2,264,311 |
Sector | Health | Technology |
52-Week High | $61.18 | $235.84 |
52-Week Low | $43.24 | $94.11 |
Typical Hold Time | 93 Days | 56 Days |
Enterprise Value | $111.88B | $44.34B |
Dividend Yield | 3.9% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
NetApp (NTAP) trades at $231.05, down 2.03% today but maintains strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), a 19.19% net income margin, and 114.82% ROE. Recent AI infrastructure announcements, including partnerships with Oracle and Supermicro, highlight strategic positioning in the growing data storage market. Analyst consensus shows mixed sentiment with 38% buy ratings but a $219.30 price target below current levels.
NetApp presents a compelling growth story driven by AI infrastructure demand and strong profitability metrics. However, elevated valuation ratios (P/E 32.63, P/S 6.26) and technical overbought conditions (RSI near 78) suggest near-term caution. The stock's upside potential depends on continued execution of AI strategy and Q3 2026 earnings delivery against $2.60 EPS expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
